Galimedix Therapeutics

Company Overview

Snapshot

Founded in June 2017 by Christopher Parsons, Herman Russ, and Andrew Pearlman, Galimedix Therapeutics operates with 1–10 employees. The company has raised $2 million across one funding round from two investors. In March 2024, Galimedix Therapeutics presented new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024.

Business overview

Galimedix Therapeutics is a Phase 2 clinical-stage company focused on developing novel oral and topical neuroprotective therapies for serious eye and brain diseases. The company's core technology involves groundbreaking small molecules designed to target amyloid beta, a key factor in neurodegeneration. Galimedix aims to revolutionize treatments for conditions such as dry Age-related Macular Degeneration (AMD), glaucoma, and Alzheimer’s disease, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In February and March 2024, Galimedix Therapeutics presented new preclinical data on GAL-201, demonstrating neuroprotective effects in an Alzheimer's disease transgenic model at the AD/PD™ 2024 Conference. This indicates continued progress in their drug discovery efforts and provides validation for their amyloid beta-targeting approach, suggesting potential for advancing their pipeline in neurodegenerative disease treatment.

Company Intelligence Q&A

What is Galimedix Therapeutics' primary focus?

Galimedix Therapeutics is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies for serious eye and brain diseases, including dry AMD, glaucoma, and Alzheimer’s disease.

When was Galimedix Therapeutics founded and by whom?

Galimedix Therapeutics was founded in June 2017 by Christopher Parsons, Herman Russ, and Andrew Pearlman.

What was the most recent scientific presentation by Galimedix Therapeutics?

In March 2024, Galimedix Therapeutics presented new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024.

Which investors participated in Galimedix Therapeutics' funding round?

In January 2019, Galimedix Therapeutics received funding from InFocus Capital Partners and Rimonci Capital.

What is the strategic significance of GAL-101's preclinical findings?

In May 2019, preclinical studies demonstrated that Galimedix Therapeutics' investigational compound GAL-101 showed a neuroprotective effect from toxic amyloid-beta in dry AMD and glaucoma models, supporting its potential in addressing neurodegenerative processes.